These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16869769)

  • 21. DNA methylation and cancer diagnosis: new methods and applications.
    Dehan P; Kustermans G; Guenin S; Horion J; Boniver J; Delvenne P
    Expert Rev Mol Diagn; 2009 Oct; 9(7):651-7. PubMed ID: 19817550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation.
    D'Alessio AC; Szyf M
    Biochem Cell Biol; 2006 Aug; 84(4):463-76. PubMed ID: 16936820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dormant hypermethylated tumour suppressor genes: questions and answers.
    Esteller M
    J Pathol; 2005 Jan; 205(2):172-80. PubMed ID: 15643671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation and colorectal cancer.
    Jubb AM; Bell SM; Quirke P
    J Pathol; 2001 Sep; 195(1):111-34. PubMed ID: 11568897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
    Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
    Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.
    Zinn RL; Pruitt K; Eguchi S; Baylin SB; Herman JG
    Cancer Res; 2007 Jan; 67(1):194-201. PubMed ID: 17210699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermethylation of tumor suppressor genes in cancer.
    Herman JG
    Semin Cancer Biol; 1999 Oct; 9(5):359-67. PubMed ID: 10547344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dialectics of cancer: A theory of the initiation and development of cancer through errors in RNAi.
    Wynter CV
    Med Hypotheses; 2006; 66(3):612-35. PubMed ID: 16359827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of DNA methylation and clinicopathological diversity of human cancers.
    Kanai Y
    Pathol Int; 2008 Sep; 58(9):544-58. PubMed ID: 18801069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
    Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
    Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation and hepatocellular carcinoma.
    Zhu J
    J Hepatobiliary Pancreat Surg; 2006; 13(4):265-73. PubMed ID: 16858536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
    Toyota M; Suzuki H; Sasaki Y; Maruyama R; Imai K; Shinomura Y; Tokino T
    Cancer Res; 2008 Jun; 68(11):4123-32. PubMed ID: 18519671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methylation, imprinting and cancer.
    Plass C; Soloway PD
    Eur J Hum Genet; 2002 Jan; 10(1):6-16. PubMed ID: 11896451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.